Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study

BACKGROUND: Lymphocyte inhibition by antagonism of α4 integrins is a validated therapeutic approach for relapsing multiple sclerosis (RMS). OBJECTIVE: Investigate the effect of CDP323, an oral α(4)-integrin inhibitor, on lymphocyte biomarkers in RMS. METHODS: Seventy-one RMS subjects aged 18–65 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Christian, Sidhu, Jagdev, Otoul, Christian, Morris, Dexter L., Cnops, Jennifer, Taubel, Jorg, Bennett, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589412/
https://www.ncbi.nlm.nih.gov/pubmed/23472197
http://dx.doi.org/10.1371/journal.pone.0058438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589412/
https://www.ncbi.nlm.nih.gov/pubmed/23472197
http://dx.doi.org/10.1371/journal.pone.0058438

Ejemplares similares